trastuzumab + lapatinib + chemotherapy

**Trastuzumab + lapatinib + chemotherapy** is a combination regimen used primarily for the treatment of HER2-positive breast cancer, including metastatic and neoadjuvant/adjuvant settings. This combination targets the human epidermal growth factor receptor 2 (HER2) pathway through two different mechanisms while incorporating cytotoxic chemotherapy. **Trastuzumab** is a monoclonal antibody targeting the extracellular domain of HER2 (ERBB2), whereas **lapatinib** is a small molecule tyrosine kinase inhibitor targeting the intracellular tyrosine kinase domains of both HER2 and epidermal growth factor receptor (EGFR/ERBB1). The combination is designed to more completely block HER2 signaling, overcome resistance to single-agent HER2-directed therapy, and induce synergistic cytotoxicity with chemotherapy. The regimen has demonstrated improved efficacy compared to single-agent HER2-directed therapy or standard chemotherapy alone in several clinical studies, but with increased toxicity. This approach is generally reserved for patients with HER2-positive advanced or metastatic breast cancer who have progressed on prior anti-HER2 therapies. The main adverse effects include diarrhea, rash, fatigue, nausea, and increased risk of cardiac toxicity and myelosuppression, depending on the chemotherapy agents used[1][2].